JANX Logo

Janux Therapeutics, Inc. (JANX) 

NASDAQ
Market Cap
$2.87B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
4 of 776
Rank in Industry
4 of 433

Largest Insider Buys in Sector

JANX Stock Price History Chart

JANX Stock Performance

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against …

Insider Activity of Janux Therapeutics, Inc.

Over the last 12 months, insiders at Janux Therapeutics, Inc. have bought $68.67M and sold $337.75M worth of Janux Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Janux Therapeutics, Inc. have bought $60.64M and sold $179.46M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $1.34B. Reardon Tighe (Acting Chief Financial Officer) — $4.99M. Lichter Jay () — $4.99M.

The last purchase of 1,200,000 shares for transaction amount of $53.7M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑10‑18.

List of Insider Buy and Sell Transactions, Janux Therapeutics, Inc.

2024-10-28SalePresident and CEO
25,000
0.0486%
$53.54$1.34M+1.60%
2024-10-18Sale10 percent owner
1.46M
2.5633%
$45.76$66.9M+8.53%
2024-10-18Purchase
1.2M
2.0576%
$44.75$53.7M+8.53%
2024-10-17Sale10 percent owner
1,843
0.0035%
$50.02$92,187+8.83%
2024-10-16Sale10 percent owner
209,516
0.4311%
$50.03$10.48M+9.49%
2024-09-30Sale10 percent owner
958
0.0018%
$46.24$44,298+8.91%
2024-09-27SalePresident and CEO
25,000
0.0476%
$46.31$1.16M+6.83%
2024-09-27SaleChief Scientific Officer
5,000
0.0095%
$46.34$231,716+6.83%
2024-09-27SaleChief Business Officer
50,000
0.0945%
$45.96$2.3M+6.83%
2024-09-27Sale10 percent owner
106,821
0.2041%
$46.46$4.96M+6.83%
2024-09-26Sale10 percent owner
200,000
0.3603%
$47.23$9.45M-0.89%
2024-09-13Sale10 percent owner
3,815
0.0068%
$46.68$178,084-1.01%
2024-09-12Sale10 percent owner
350,000
0.6777%
$47.00$16.45M+6.49%
2024-09-10Sale10 percent owner
101,091
0.1981%
$46.53$4.7M+8.75%
2024-09-09Sale10 percent owner
2,182
0.0042%
$42.33$92,364+18.18%
2024-09-06Sale10 percent owner
240,000
0.4683%
$42.00$10.08M+19.81%
2024-06-03SaleActing Chief Financial Officer
822,721
1.5801%
$54.75$45.04M-18.76%
2024-06-03Sale
1.5M
2.8808%
$54.75$82.13M-18.76%
2024-06-03Sale10 percent owner
1.5M
2.8808%
$54.75$82.13M-18.76%
2023-11-13PurchaseActing Chief Financial Officer
849,854
1.538%
$5.87$4.99M+483.10%

Insider Historical Profitability

1.61%
RA CAPITAL MANAGEMENT, L.P.
9317246
17.8613%
$54.9730+1.61%
Reardon TigheActing Chief Financial Officer
633673
1.2148%
$54.9721+1.61%
Avalon Ventures XI, L.P.10 percent owner
401321
0.7693%
$54.97211+1.61%
Lichter Jay10 percent owner
7000
0.0134%
$54.9722+1.61%
Bregua Corp10 percent owner
3749250
7.1874%
$54.9710+1.61%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$345.09M17.689.17M0%+$00.35
Fidelity Investments$291.75M14.957.75M+65.89%+$115.88M0.02
OrbiMed$160.97M8.254.28M+28.86%+$36.05M1.24
Bvf Inc Il$109.93M5.632.92M-36.25%-$62.5M0.81
Adage Capital Partners Gp L L C$104.5M5.352.78M+104.78%+$53.47M0.19
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.